Twinbeech Capital LP Has $912,000 Stake in Hologic, Inc. (NASDAQ:HOLX)

Twinbeech Capital LP trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 68.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,657 shares of the medical equipment provider's stock after selling 28,077 shares during the period. Twinbeech Capital LP's holdings in Hologic were worth $912,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of HOLX. Barclays PLC lifted its holdings in shares of Hologic by 47.6% during the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock valued at $58,507,000 after purchasing an additional 231,578 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Hologic by 4.1% during the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after purchasing an additional 188 shares during the last quarter. LaFleur & Godfrey LLC lifted its holdings in shares of Hologic by 2.9% during the fourth quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock valued at $9,399,000 after purchasing an additional 3,655 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Hologic by 80.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 32,588 shares of the medical equipment provider's stock valued at $2,349,000 after purchasing an additional 14,487 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Hologic by 44.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock valued at $4,595,000 after purchasing an additional 19,688 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Up 1.0%

Shares of HOLX traded up $0.52 during midday trading on Tuesday, reaching $54.80. 527,232 shares of the stock were exchanged, compared to its average volume of 2,138,613. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The firm has a 50 day simple moving average of $58.02 and a 200-day simple moving average of $66.26. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company has a market cap of $12.21 billion, a price-to-earnings ratio of 17.29, a P/E/G ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the business earned $1.03 EPS. The business's quarterly revenue was down 1.2% on a year-over-year basis. Research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

HOLX has been the subject of several analyst reports. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Royal Bank of Canada reduced their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Evercore ISI reduced their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. Stephens reduced their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Finally, Raymond James reissued an "outperform" rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Hologic has an average rating of "Hold" and a consensus price target of $77.42.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus acquired 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director now owns 5,445 shares in the company, valued at approximately $300,781.80. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.88% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.